



contacted with a phagocyte, and a complex formed between the phagocyte-recognizing agent and the phagocyte is detected.

6. (Cancel)
7. (Withdrawn) Method according to claim 6, wherein the agent is a bacteriophage.
8. (Withdrawn) Method according to claim 6, wherein the agent is a fluorescent agent.
9. (Withdrawn) Method according to claim 8, wherein the agent comprises Green or Blue Fluorescent Protein.
10. (Withdrawn) Method according to claim 8, wherein detection is performed by means of a Fluorescence-Activated Cell Sorter (FACS).
11. (Withdrawn) Method according to claim 5, wherein the detection is performed by means of an ELISA.
12. (Withdrawn) Method according to claim 5, wherein the phagocyte is derived from a person of which it is thought that it suffers from an affection chosen from the group consisting of i) organ-bound inflammatory diseases; ii) septic shock; iii) allergies; and iv) auto-immune diseases; or of a person having undergone a transplantation.
13. (Withdrawn) Method according to claim 12, wherein for detection blood from a person is lysed using an isotonic, cold  $\text{NH}_4\text{Cl}$ -solution yielding a phagocyte-containing solution.
14. (Cancel)

15. (Currently Amended) The phagocyte-recognizing agent of claim [[14]] 2, which comprises an antigen-binding part of an antibody.
16. (Previously Presented) The phagocyte-recognizing agent of claim 15, which is a monoclonal antibody.
17. (Currently Amended) The phagocyte-recognizing agent of claim 2, which comprises the ~~antigen-specific~~ antigen-recognizing sequence of a bacteriophage from a strain selected from the strains having accession numbers CBS101481 and CBS101482.
18. (Currently Amended) A phagocyte-binding agent ~~capable~~ having the property of competitively inhibiting the binding of a bacteriophage isolated from a strain selected from CBS 101481 and CBS 101482 to a preactivated phagocyte.
19. (Currently Amended) The phagocyte-binding agent of claim 18, wherein the ~~phagocyte~~ phagocyte is a GM-CSF primed leukocyte.
20. (Currently Amended) The phagocyte-binding agent of claim 18, wherein the phagocyte-binding agent comprises an antigen-binding ~~part~~ fragment of an antibody.
21. (Previously Presented) The phagocyte-binding agent of claim 20, which is a monoclonal antibody.
22. (Previously Presented) The pharmaceutical composition of claim 4, wherein the phagocyte-recognizing agent comprises an antigen-binding part of an antibody capable of competing with the bacteriophage in binding to a GM-CSF primed granulocyte.
23. (New) The phagocyte-recognizing agent of claim 2, wherein the agent is an ScFv fragment with the antigen-recognizing sequence of

bacteriophage isolated from the strain having accession number CBS  
101481.

24. (New) The phagocyte-recognizing agent of claim 2, wherein the agent is  
a humanized antibody with the antigen-recognizing sequence of  
bacteriophage isolated from the strain having accession number CBS  
101481.